Venture-Backed Startups
125,471 companies with verified investor relationships.
Biosapien develops treatments for cancer that are delivered locally to shrink tumors, relieve symptoms, and reduce the need for surgeries.
3 investors
0 investors
BioScape Digital provides interactive patient-facing tools combining audio, text and visual media for healthcare settings, including educational content, provider tools, real-time patient satisfaction feedback, and games to occupy patients during wait times. The product is aimed at healthcare providers to support patient care and engagement.
0 investors
Bioscibex develops SW1NGO, a single-use system that automates the seed train in biologics manufacturing by scaling directly from 30 mL up to 30 L in one step, eliminating manual cell passaging and reducing contamination risks. It targets biopharma companies and CDMOs involved in upstream process development and manufacturing.
1 investor
0 investors
0 investors
BioScout provides autonomous, solar-powered air sampling devices that detect airborne fungal spores using high-resolution microscopy, delivering spore data to a dashboard so growers, agronomists, and researchers can time fungicide sprays and prevent crop disease. The system aims to reduce fungicide use and protect yield in agriculture.
1 investor
0 investors
0 investors
BioSeek builds an AI platform for drug discovery that unifies fragmented biological sources—literature, patents, clinical, and chemistry data—into a connected knowledge graph, with specialist agents that reason across it from disease biology to safety-screened molecules. The software is deployed inside a customer's own infrastructure so proprietary data and tools join the private graph without leaving their environment, targeting enterprise pharma and biotech research teams.
1 investor
Sens.bio manufactures a portable device for on-site detection of mycotoxins in grains and animal feed using a test cartridge and mobile app data analysis. The device serves agronomic researchers, farms, and grain storage operators to assess crop and feed contamination quickly without laboratory analysis.
1 investor
BioSens8 develops a platform that identifies microbes to engineer biosensors for quantitative, real-time, and continuous monitoring. The company is expanding its biosensor technology beyond glucose monitoring.
1 investor
Biosense Technologies develops user-friendly medical devices for basic screening tests, aimed at reducing the load on primary healthcare services and enabling users to screen and manage conditions in real time. Its focus areas include diseases such as diabetes, heart disease, and cancer.
1 investor
BioSerenity develops and manufactures CE- and FDA-approved electrophysiological medical devices, AI, and software to capture and analyze EEG, ECG, and PSG signals for diagnosing neurological and cardiac disorders. It serves clinics and medical centers, providing AI-assisted neurophysiological diagnostics.
2 investors
0 investors
0 investors
Biosight was a pharmaceutical company that merged with Ayala Pharmaceuticals on October 19, 2023.
1 investor
0 investors
Biosimo produces bio-based platform chemicals — with bio-acetic acid as its flagship, plus acetaldehyde, ethyl acetate, and bio-VAM — by converting bioethanol using a proprietary heterogeneous catalyst in a single continuous fixed-bed reactor step. The company, an ETH Zurich spin-off, sells to industries including agriculture, automotive, construction, home care, and cosmetics, aiming to compete at fossil-fuel economics.
2 investors
0 investors
BioSkryb Genomics develops single-cell multiomics technology, including its patented primary template-directed amplification (PTA) method and ResolveDNA, ResolveOME kits and BaseJumper bioinformatics platform, to analyze the genome, transcriptome, and surface proteins of individual cells. Its products serve research, biopharma, diagnostics, and AI-driven precision medicine partners working in oncology, neurology, and clinical development.
2 investors
0 investors
0 investors
Biosortia is a drug discovery company whose Industrial-Scale Microbiome Mining (ISMM) platform extracts community-derived small molecules from the microbiome at kilogram-to-ton scale, using an AI tool (BiosortAI) to prioritize evolutionarily shaped compounds. Its lead program targets obesity and metabolic disease, with expansion into IBD, gut-brain neuromodulation, oncology, pain, and anti-infectives.
1 investor